This is such bad news, I will post the whole announcement here:
In a first, Geron made headlines at the BIO CEO conference in New York with its announcement that it could begin its first human trials using embryonic stem cells to treat spinal cord injuries as early as this spring. Geron first has to meet the “high bar” set by the FDA, says Geron CEO Thomas Okarma. Geron is in a race to start the first FDA-approved ESC trials. Advanced Cell Technology, which has been trying–unsuccessfully so far–to find a way around the controversy generated by ESCs by creating new stem cell lines without destroying embryos, also plans to launch human trials this year. Novocell is believed to be further back in the field. But no one believes that FDA approval will be quick and easy.
“This is the first time that a human embryonic stem cell application is being submitted to the FDA, so there’s a good chance that some questions will arise,” said Ren Benjamin, analyst for Rodman & Renshaw.
A significant crowd has turned out for the annual biotech confab. Organizers of the conference estimate attendance at around 2,500, noting an increase over last year’s gathering of biotech executives.
Author Profile
- Jennifer Lahl, MA, BSN, RN, is founder and president of The Center for Bioethics and Culture Network. Lahl couples her 25 years of experience as a pediatric critical care nurse, a hospital administrator, and a senior-level nursing manager with a deep passion to speak for those who have no voice. Lahl’s writings have appeared in various publications including Cambridge University Press, the San Francisco Chronicle, the Dallas Morning News, and the American Journal of Bioethics. As a field expert, she is routinely interviewed on radio and television including ABC, CBS, PBS, and NPR. She is also called upon to speak alongside lawmakers and members of the scientific community, even being invited to speak to members of the European Parliament in Brussels to address issues of egg trafficking; she has three times addressed the United Nations during the Commission on the Status of Women on egg and womb trafficking.
Latest entries
FeaturedSeptember 9, 2024Don’t Make Claims Using Outdated Data
BioethicsMay 16, 2024The Ethics of Transplantation Medicine
infertilityApril 23, 2024The Rise of International Gestational Surrogacy in the U.S.
Assisted Reproductive TechnologyApril 16, 2024Founder Jennifer Lahl’s Speech on Surrogacy to the Casablanca Declaration
